Inhibition of the Tf-TfR1 axis using anti-TfR1 antibody attenuates ANKL. (A) Schema for assessing the therapeutic efficacy of PPMX-T003 for ANKL in a preclinical setting. ANKL-PDX mice were treated with PBS or 10 mg/kg of PPMX-T003 on days 5, 8, 12, and 15 after transplantation of 1 × 106 ANKL cells and monitored until the end point. (B) Survival curve of ANKL1, ANKL3, and ANKL5 PDX mice treated with PBS or PPMX-T003 (n = 3-4 in each group). (C) Schema for evaluating the efficacy of PPMX-T003 treatment in PDX mice with advanced disease. ANKL-PDX mice were treated with PBS or 10 mg/kg of PPMX-T003 on days 14, 17, 21, and 24 after transplantation of 1 × 106 ANKL1 cells and monitored until the end point. (D) Relative weight changes of mice during the course of the experiment. Weights were corrected for body weight on day 14. (E) Survival curve of ANKL1-PDX mice treated with PBS or PPMX-T003 (n = 6). (F) IVIS analysis of ANKL1-PDX mice treated with 10 mg/kg of PPMX-T003 or PBS on days 14, 17, 21, and 24. Representative image from 3 biological replicates. (G) H&E staining (left) and CD56 IHC (right) for a liver section from ANKL1-PDX mice before and after the PPMX-T003 treatment. Scale bar, 100 μm. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.
